Dermatology Research and Practice

Research Article

Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris

Table 3

Synopsis of the IgG autoantibody profile of the pemphigus vulgaris (PV) patients prior to rituximab (preRtx) treatment and at the time of clinical relapse (CR).
IgG against extracellular subdomains of Dsg3
Dsg3EC1Dsg3EC2Dsg3EC3Dsg3EC4Dsg3EC5
Time pointpreRtx6 monthsCRpreRtx6 monthsCRpreRtx6 monthsCRpreRtx6 monthsCRpreRtx6 monthsCR
PV3 (CR, months 12)+++−++−−−−++−−−
PV5 (CR, months 12)−−−−−++−++++−−−
PV6 (CR, months 12)+−+−−−−−−−−−−−−
PV13 (CR, months 18)+−+−−−−−−+−+−−−
PV19 (CR, months 18)+++−−−−−−−−+−−−
PV23 (CR, months 18)−−+−−−−−−++++−−